Suven Life Sciences has informed that it enclosed News Release of the company titled ‘Suven Life Sciences announces successful completion and topline results of First-in-Human (FIH) Phase-1 clinical study of SUVN-I6107, a Muscarinic M1 Positive Allosteric Modulator (M1-PAM) and its advancement into Phase-2 clinical development’.
The above information is a part of company’s filings submitted to BSE.